Literature DB >> 31171314

Opportunities and challenges in the treatment of psoriatic arthritis.

Oliver FitzGerald1, Christopher Ritchlin2.   

Abstract

In this chapter, we review the opportunities and challenges posed by the treatment options currently available in the treatment of psoriatic arthritis. Both established and new or emerging treatment options are discussed using a domain-based approach. Finally, approaches to how treatment can be optimized together with some clinical pearls are presented and discussed. With the increasing treatment options available, we need a better way of deciding which treatment should be considered for which patient. On the basis of current knowledge, some guidance is provided on how these choices might best be made.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biologic agents; Disease modification; Domains; Psoriatic arthritis

Mesh:

Substances:

Year:  2019        PMID: 31171314     DOI: 10.1016/j.berh.2019.03.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  2 in total

1.  Evolution of patient characteristics in the era of biologic treatment of psoriatic arthritis: 18-year Belgian experience from the Leuven Spondyloarthritis Biologics Cohort (BioSPAR).

Authors:  Alla Ishchenko; Johan Joly; Barbara Neerinckx; Rik Lories; Kurt de Vlam
Journal:  Rheumatol Adv Pract       Date:  2021-11-15

2.  TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA).

Authors:  Nienke J Kleinrensink; Frank T Perton; Juliëtte N Pouw; Nanette L A Vincken; Sarita A Y Hartgring; Mylène P Jansen; Saeed Arbabi; Wouter Foppen; Pim A de Jong; Janneke Tekstra; Emmerik F A Leijten; Julia Spierings; Floris P J G Lafeber; Paco M J Welsing; Marloes W Heijstek
Journal:  BMJ Open       Date:  2022-10-10       Impact factor: 3.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.